Patents by Inventor Paul Michael Scola

Paul Michael Scola has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS USEFUL AS IMMUNOMODULATORS
    Publication number: 20240124417
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: October 1, 2020
    Publication date: April 18, 2024
    Applicant: Bristol-Myers Squibb Company
    Inventors: Kap-Sun YEUNG, Denis R. ST. LAURENT, Li-Qiang SUN, Zhiwei YIN, Katharine A. GRANT-YOUNG, Paul Michael SCOLA
  • IMMUNOMODULATORS
    Publication number: 20230242585
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PDL 1 and PD-L 1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: May 7, 2021
    Publication date: August 3, 2023
    Inventors: Tao WANG, Paul Michael SCOLA, Zhongxing ZHANG
  • IMMUNOMODULATORS
    Publication number: 20230101323
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: April 20, 2022
    Publication date: March 30, 2023
    Applicant: Bristol-Myers Squibb Company
    Inventors: Kevin W. GILLMAN, Jason GOODRICH, Kenneth M. BOY, Yunhui ZHANG, Claudio MAPELLI, Michael A. POSS, Paul Michael SCOLA, David R. LANGLEY, Nicholas A. MEANWELL
  • IMMUNOMODULATORS
    Publication number: 20230063238
    Abstract: In accordance with the present disclosure, macrocyclic compounds of formula (I) have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.
    Type: Application
    Filed: November 19, 2020
    Publication date: March 2, 2023
    Applicant: Bristol-Myers Squibb Company
    Inventors: Tao WANG, Paul Michael SCOLA, Zhongxing ZHANG
  • IMMUNOMODULATORS
    Publication number: 20230065827
    Abstract: In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.
    Type: Application
    Filed: November 19, 2020
    Publication date: March 2, 2023
    Applicant: Bristol-Myers Squibb Company
    Inventors: Tao WANG, Paul Michael SCOLA, Zhongxing ZHANG
  • Compounds useful as immunomodulators
    Patent number: 11578054
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: February 14, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, Denis R. St. Laurent, David R. Langley, Paul Michael Scola
  • IMMUNOMODULATORS
    Publication number: 20230022400
    Abstract: In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.
    Type: Application
    Filed: November 19, 2020
    Publication date: January 26, 2023
    Inventors: Tao WANG, Paul Michael SCOLA, Zhongxing ZHANG
  • IMMUNOMODULATORS
    Publication number: 20220389061
    Abstract: In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.
    Type: Application
    Filed: October 29, 2020
    Publication date: December 8, 2022
    Inventors: Tao WANG, Paul Michael SCOLA, Zhongxing ZHANG
  • Compounds useful as immunomodulators
    Patent number: 11414418
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: August 16, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, Juliang Zhu, Paul Michael Scola
  • Immunomodulators
    Patent number: 11358988
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: June 14, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell
  • Immunomodulators acting as antagonists of PD-1
    Patent number: 11066445
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: July 20, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kevin W. Gillman, Jason Goodrich, Li-Qiang Sun, Eric Mull, David R. Langley, Paul Michael Scola
  • Substituted isoquionline derivatives as immunomudulators
    Patent number: 11046675
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various pp diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: June 29, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, Denis R. St. Laurent, Jeffrey Lee Romine, Paul Michael Scola
  • Immunomodulators
    Patent number: 10988507
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: April 27, 2021
    Assignee: bristol-myers squibb company
    Inventors: Kevin W. Gillman, Jason Goodrich, David R. Langley, Paul Michael Scola
  • COMPOUNDS USEFUL AS IMMUNOMODULATORS
    Publication number: 20210094932
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: February 28, 2019
    Publication date: April 1, 2021
    Inventors: Kap-Sun YEUNG, Denis R. ST. LAURENT, David R. LANGLEY, Paul Michael SCOLA
  • COMPOUNDS USEFUL AS IMMUNOMODULATORS
    Publication number: 20210053972
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: January 23, 2019
    Publication date: February 25, 2021
    Inventors: Kap-Sun YEUNG, Juliang ZHU, Paul Michael SCOLA
  • Compounds useful as immunomodulators
    Patent number: 10745382
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: August 18, 2020
    Assignee: bristol-myers squibb company
    Inventors: Kap-Sun Yeung, Timothy P. Connolly, David B. Frennesson, Katharine A. Grant-Young, Piyasena Hewawasam, David R. Langley, Zhaoxing Meng, Eric Mull, Kyle E. Parcella, Mark George Saulnier, Li-Qiang Sun, Alan Xiangdong Wang, Ningning Xu, Juliang Zhu, Paul Michael Scola
  • IMMUNOMODULATORS
    Publication number: 20200216498
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: December 11, 2019
    Publication date: July 9, 2020
    Applicant: Bristol-Myers Squibb Company
    Inventors: Kevin W. GILLMAN, Jason GOODRICH, Kenneth M. BOY, Yunhui ZHANG, Claudio MAPELLI, Michael A. POSS, Paul Michael SCOLA, David R. LANGLEY, Nicholas A. MEANWELL
  • SUBSTITUTED ISOQUIONLINE DERIVATIVES AS IMMUNOMUDULATORS
    Publication number: 20200181125
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various pp diseases, including cancer and infectious diseases.
    Type: Application
    Filed: March 26, 2018
    Publication date: June 11, 2020
    Applicant: Bristol-Myers Squibb Company
    Inventors: Kap-Sun YEUNG, Denis R. ST. LAURENT, Jeffrey Lee ROMINE, Paul Michael SCOLA
  • IMMUNOMODULATORS ACTING AS ANTAGONISTS OF PD-1
    Publication number: 20200172578
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 pro-tein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: June 21, 2018
    Publication date: June 4, 2020
    Applicant: Bristol-Myers Squibb Company
    Inventors: Kevin W. GILLMAN, Jason GOODRICH, Li-Qiang SUN, Eric MULL, David R. LANGLEY, Paul Michael SCOLA
  • Immunomodulators
    Patent number: 10633419
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: April 28, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell